Anavex Life Sciences Corp (AVXL)

[Robot14]

While I agree with most of your timeline and PPS forecasts, I can’t see Misslings selling at $150 a share which is about $13.2B MC.
That is $2B less than Karuna was bought for, albeit almost $2B was debt which was absorbed.
A successful 3-71 for schizophrenia alone would be worth the $13B valuation, then add in an approved 2-73 for AD.
We dont need the upfront cash from a partnership, Anavex can afford to be choosy on whom they partner with & terms.
Any buyout should be in the $18B range for around $200 a share, at 90M fully diluted outstanding shares. JMO